<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849873</url>
  </required_header>
  <id_info>
    <org_study_id>V01-123A-501</org_study_id>
    <nct_id>NCT02849873</nct_id>
  </id_info>
  <brief_title>Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream</brief_title>
  <official_title>Randomized Study Evaluating the Absorption and Systematic Pharmacokinetics of Topically Applied IDP-123 Lotion in Comparison With Tazorac Cream in Subjects With Moderate to Severe Acne Vulgaris Under Maximal Use Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison with Tazorac
      Cream.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized study evaluating the absorption and systematic pharmacokinetics of IDP-123 lotion
      in comparison with Tazorac Cream in subjects with moderate to severe acne vulgaris under
      maximal use conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluator's Global Severity Score: At Day 15 (or ET), acne severity will be determined by the investigator/evaluator based on a global assessment of the inflammatory and non-inflammatory lesions of facial acne.</measure>
    <time_frame>15 Days</time_frame>
    <description>Evaluations will be graded on a static scale ranging from 0 (clear) to 4 (severe)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>IDp-123 Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lotion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tazorac Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-123 Lotion</intervention_name>
    <description>Lotion</description>
    <arm_group_label>IDp-123 Lotion</arm_group_label>
    <other_name>IDP-123</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazorac Cream</intervention_name>
    <description>Cream</description>
    <arm_group_label>Tazorac Cream</arm_group_label>
    <other_name>Tazorac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female, at least 9 years of age (at least 12 years of age for Tazorac Cream).

          -  Verbal and written informed consent must be obtained. Subjects less than age of
             consent must sign an assent for the study and a parent or a legal guardian must sign
             the informed consent (if the subject reaches age of consent during the study they
             should be re-consented at the next study visit).

          -  Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global
             Severity assessment at the screening and baseline visit.

          -  Subjects with facial acne inflammatory lesion count no less than 20 but no more than
             40.

          -  Subjects with facial acne non-inflammatory lesions count no less than 20 but no more
             than 100.

        Key Exclusion Criteria:

          -  Use of an investigational drug or device within 30 days of enrollment or participation
             in a research study concurrent with this study.

          -  Any dermatological conditions on the face that could interfere with clinical
             evaluations such as acne conglobate, acne fulminans, secondary acne, perioral
             dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis,
             eczema.

          -  Any underlying disease or some other dermatological condition of the face that
             requires the use of interfering topical or systemic therapy or makes evaluations and
             lesion count inconclusive.

          -  Subjects with a facial beard or mustache that could interfere with the study
             assessments.

          -  Subjects with more than 2 facial nodules.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anya Loncaric</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazarotene</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

